Monday, July 11, 2011
Sunshine Biopharma, a development stage pharmaceutical company, has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results showed that Adva-27a is 16 times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug. Data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.